OAC
CBIO

OMERS Administration Corp’s Crescent Biopharma CBIO Stock Holding History

OMERS Administration Corp’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Buy
17,800
+6,200
+53% +$71.2K ﹤0.01% 843
2025
Q4 		$138K Buy
+11,600
New +$148K ﹤0.01% 949
2024
Q2 		– Sell
-306
Closed -$91.8K – 1115
2024
Q1 		$91.8K Buy
+306
New +$91.4K ﹤0.01% 329

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OMERS Administration Corp's CBIO Position: Q1 2026 in Review

OMERS Administration Corp increased its Crescent Biopharma (CBIO) stake by 53% in Q1 2026, buying an estimated $71.2K and bringing the position to 17,800 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #843.

OMERS Administration Corp first reported a position in CBIO in Q1 2024 and has held it in 3 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • OMERS Administration Corp held 17,800 shares of Crescent Biopharma worth $327K as of Q1 2026.
  • OMERS Administration Corp bought 6,200 Crescent Biopharma shares in Q1 2026, an estimated $71.2K.
  • Crescent Biopharma made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #843 holding.
  • OMERS Administration Corp first reported a position in Crescent Biopharma in Q1 2024 and has held it in 3 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.